Revenio Group Corporation: Transfer of the Company's own shares
Revenio Group Corporation, Stock Exchange Release, May 3, 2018 at 14.00
Transfer of the Company's own shares
Revenio Group Corporation has transferred on May 3, 2018 4,164 shares (REG1V) to the members of the Board of Directors as part of remuneration of the Board.
Revenio Group Corporation's AGM decided on March 20, 2018 that 40% of the fee paid to a board member should be paid in company shares while 60% will comprise a monetary payment. The AGM decided that the Chair of the Board be entitled to an annual emolument of EUR 48,000 and the other Board members to an annual emolument of EUR 24,000.
As a result of these transfers, the share-based board member fees have been completely settled for the year 2018. Revenio Group Corporation now holds a total of 6,213 of its own shares.
Revenio Group Corporation
For further information, please contact:
Timo Hildén, CEO, tel. +358 40 580 4774
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2017, net sales of Revenio Group totaled MEUR 26.8, with an operating margin of 35.5%, excluding non-recurring expenses. Revenio Group Corporation is listed on Nasdaq Helsinki.